Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997815 | 0.83 | SLC6A2 (0.55) | SLC6A4SLC6A2GAA | |
| SCHEMBL18997814 | 0.79 | GAA (0.57) | HTR2ASLC6A4SLC6A2GAA | |
| SCHEMBL19002825 | 0.75 | GAA (0.73) | HTR2ASLC6A4SLC6A2GAA | |
| SCHEMBL20778680 | 0.74 | SLC6A4 (0.50) | HTR2ASLC6A4SLC6A2 | |
| SCHEMBL24943172 | 0.73 | OPRM1 (0.51) | SLC6A4SLC6A2 | |
| SCHEMBL21900761 | 0.72 | OPRM1 (0.53) | SLC6A4SLC6A2 | |
| SCHEMBL20780557 | 0.72 | HTR2A (0.85) | HTR2A | |
| SCHEMBL20218988 | 0.72 | PSMB5 (0.44) | — | |
| SCHEMBL31649396 | 0.70 | HTR2A (0.56) | HTR2ASLC6A4SLC6A2 | |
| SCHEMBL18383633 | 0.69 | PKM (0.43) | HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | HTR2A 4083/4885SLC6A4 4664/4885SLC6A2 4684/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | HTR2A 4536/4885SLC6A4 4710/4885SLC6A2 4742/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | HTR2A 4536/4885SLC6A4 4710/4885SLC6A2 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.